SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-021643
Filing Date
2024-02-28
Accepted
2024-02-28 07:02:43
Documents
17
Period of Report
2024-02-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pyxs-20240226.htm   iXBRL 8-K 54227
2 EX-4.1 pyxs-ex4_1.htm EX-4.1 170988
3 EX-10.1 pyxs-ex10_1.htm EX-10.1 461683
4 EX-10.2 pyxs-ex10_2.htm EX-10.2 232295
5 EX-99.1 pyxs-ex99_1.htm EX-99.1 16437
6 GRAPHIC img244827169_0.jpg GRAPHIC 7119
  Complete submission text file 0000950170-24-021643.txt   1191870

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pyxs-20240226.xsd EX-101.SCH 25998
18 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20240226_htm.xml XML 4911
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

IRS No.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 24690127
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)